Vor Bio prices $100 million public offering of common stock

BOSTON - Vor Biopharma Inc. (Nasdaq:VOR) announced Monday the pricing of an underwritten public offering of 10 million shares of its common stock at $10.00 per share, expecting to raise $100 million in gross proceeds. The offering comes as the stock trades at $18.80, having experienced a dramatic 521% surge over the past six months despite recent weakness, according to InvestingPro data.

The clinical-stage biotechnology company, which focuses on developing treatments for autoimmune diseases, said the offering is expected to close around November 12, 2025, subject to customary closing conditions.

Vor Bio has granted underwriters a 30-day option to purchase up to an additional 1.5 million shares at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the offering, according to the company's press release statement.

The company is offering the shares pursuant to a shelf registration statement that was declared effective by the Securities and Exchange Commission on March 31, 2025.

Vor Bio is currently advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for autoantibody-driven conditions.

The company did not specify how it plans to use the proceeds from the offering in its announcement.

In other recent news, Vor Biopharma Inc. has announced the commencement of a $100 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to $15 million more shares. J.P. Morgan, Jefferies, Citigroup, and TD Cowen are serving as joint book-running managers for this offering. The company also reported promising results from its Phase 3 clinical study in China for its IgA nephropathy drug, telitacicept, which showed a 55% reduction in proteinuria compared to placebo. Additionally, Vor Bio's collaborator, RemeGen Co., presented positive 48-week extension data for telitacicept in patients with generalized myasthenia gravis, showing significant improvements in the Myasthenia Gravis Activities of Daily Living scale. Furthermore, Vor Bio has appointed Jeremy Sokolove, M.D., as its new Chief Medical Officer, bringing over 20 years of experience in rheumatology and autoimmune disease research. These developments reflect the company's ongoing efforts in advancing its clinical programs and expanding its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.